2023
DOI: 10.3390/cells13010030
|View full text |Cite
|
Sign up to set email alerts
|

Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?

Justyna Woś,
Agata Szymańska,
Natalia Lehman
et al.

Abstract: Galectin-3’s (Gal-3) effect on the pathogenesis of chronic lymphocytic leukemia (CLL) has not yet been extensively studied. The present study aims to analyze the potential role of Gal-3 as a prognostic biomarker in CLL patients. The Gal-3 expression was evaluated in CLL cells with RT-qPCR and flow cytometry. Due to the unclear clinical significance of soluble Gal-3 in CLL, our goal was also to assess the prognostic value of Gal-3 plasma level. Because cell survival is significantly affected by the interaction … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 48 publications
0
0
0
Order By: Relevance